Ann: Clinical Trial Update, page-12

You know the more I think about ftt the more I think it’s a compelling investment case.

$30M market cap for a company with a phase two trial well under way. If successful it is a potential platform for launching the product in Europe and a pharma deal for phase 3 in the us. Plus a pipeline of products for other indications.

Yes they will probably have to raise a little money before the trial readout, but they have the capability to do this quickly and efficiently to sophisticated investors when the time comes.

If you hear a beeping noise, it might just be me backing up the truck.